ImpediMed announced a new medical device yesterday, which it said had great potential to impact the market for heart failure treatment.
The Australian reports that the ASX-listed company – which uses electric current to measure changes in a user’s body – announced it was preparing to have its new product for sale by August 2017. The device, named Sozo, measures fluid changes to help manage chronic health problems, including those of the heart.
“The new platform will give you body composition, fluid analysis, fat analysis … with that you can manage the diet of the patients, as well as measuring for lymphoedema,” The Australian reports CEO Rick Carreon as saying.
“The patient can have one of these devices at home and only go to a medical centre when they see elevated scores.”
Carreon called Sozo a “game-changer” for managing heart conditions, with heart failure a massive challenge predicted to be worth $US 70 billion by 2030.
ImpediMed’s devices us “bioimpedance spectroscopy” to determine changes to body fluid through small electrical currents. “The level of impedance or resistance of a patient’s body to the current can be measured and converted into clinically useful measurements such as a patient’s fat mass, fat free mass and fluid levels,” its website explains.
The company’s devices are currently used for lymphedema (fluid retention), fluid status/body composition, and research applications.